<DOC>
	<DOCNO>NCT00276536</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell slow growth cancer . PURPOSE : This phase I trial study side effect best dose interferon alfa treat patient stage IV solid tumor , lymphoma , myeloma .</brief_summary>
	<brief_title>Interferon Alfa Treating Patients With Stage IV Solid Tumors , Lymphoma , Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Confirm tolerance safety interferon alfa-1b ( IFN-α1b ) patient stage IV solid tumor , lymphoma , myeloma . - Determine maximum tolerate dose ( MTD ) IFN-α1b give daily subcutaneous injection patient . OUTLINE : This dose-escalation study . Patients receive interferon alfa-1b subcutaneously daily least 1 month . Treatment continue 12 month absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos interferon alfa-1b maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy , include , limited , renal cell carcinoma , melanoma , Kaposi 's sarcoma , breast carcinoma , lymphoma , myeloma , tumor endothelial origin Stage IV disease Refractory standard therapy Measurable evaluable disease Evaluable disease include clinically radiographically nonmeasurable tumor specific tumor marker Patients prior solitary CNS metastasis allow Must prior definitive therapy ≥ 3 month previously No requirement glucocorticoid unless physiologic replacement No multiple CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.3 time upper limit normal ( ULN ) OR Creatinine clearance 60 mL/min Bilirubin ≤ 1.3 time ULN AST ≤ 5 time ULN No pregnant lactate woman Fertile woman men , unless surgically sterile , must use effective contraception No history serious cardiac arrhythmia cardiac arrhythmia require treatment No congestive heart failure No angina pectoris No New York Heart Association class III IV disease No severe cardiovascular disease No known seizure disorder No known HIV hepatitis B surface antigen positivity No active clinical infection require antibiotic within past 7 day PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 month since prior interferon therapy and/or ≤ 400 million unit interferon At least 3 week since prior major surgery require general anesthesia At least 3 week since prior radiotherapy chemotherapy Treatment hormones chemotherapeutic agent may administer except steroid give preexist adrenal failure hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) No prior organ allograft No concurrent dexamethasone , steroidal antiemetic , antiinflammatories No concurrent palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>